Since its establishment in 1969, ELPEN has primarily focused on the development, production, and distribution, of a wide range of high-quality branded generics.
Today, based on the wide recognition our company enjoys from the Greek medical community, ELPEN has developed an important network of prestigious Greek and international development partners. The plethora of successful launches for key generic products has made ELPEN the partner of choice for the largest international companies.
Furthermore, the approach of "first generic to the market" concept, following the patent expiration of the reference products, has been the key factor to ELPEN's exponential growth.
The branded generics which is the core business of ELPEN,exceeded €80 million turnover in 2010 contributing thus to 65% of the company's total turnover, and as a result, ranking ELPEN among the leading Greek pharmaceutical companies(source: IMS 2010).
An integral part of our identity is our strategic focus on building strong brands in the analogous markets, while maintaining the highest quality standards.
We pride ourselves for building strong business partnerships and we welcome all proposals that create a mutually beneficial value between ELPEN and the selected partner(s).